ARCH Venture Partners
ARCH Venture Partners invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH Ventures enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. For more information visit www.archventure.com.
Casdin Capital is an investment firm founded in 2011 with offices in New York and San Diego. Our firm actively seeks out life science innovation that disrupts the diagnostic, drug development and industrial biotechnology business models, dramatically improving quality of life and generating substantial long term investment returns along the way.
The firm’s investment philosophy is rooted in a conviction that business success is defined by the people managing the business. Our approach is to leverage our deep domain expertise and extensive proprietary research process to identify and invest in great people targeting large market opportunities.
Long-term capital appreciation is the product of patience and persistence (investment conviction). As investors awaken to an opportunity and capital begins to move in its direction, its momentum takes a long time to be spent, resulting in dramatic appreciations of value. We position ourselves to capitalize on these long-term opportunities in the life science sector.
Keith L. Crandell
Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory.
Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, and Ciespace. Mr. Crandell also serves as a director of the Illinois Venture Capital Association.
Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.
Jay Flatley has served as CEO and director of Illumina, Inc. since October 1999. He drives strategic vision for the company and manages its commercial and corporate functions. With the company’s initial success in genotyping and subsequent expansion into whole-genome sequencing, diagnostics and informatics, sales grew from $1.3 million in 2000 to more than $1.4 billion in 2013. Under Mr. Flatley’s leadership, the company has launched over 60 major products, acquired several new technologies, and entered multiple markets in the research, applied, and clinical arenas. Prior, Mr. Flatley was co-founder, President, and CEO of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.
E. Kevin Hrusovsky was appointed President, Life Sciences and Technology, PerkinElmer following PerkinElmer’s acquisition of Caliper (CALP). Kevin served as CEO of Caliper Life Sciences from July 2003, when Zymark Corporation was acquired by Caliper. With a strong commercialization and external focus, Caliper was transformed into a leading edge personalized medicine / health technology company. Its market value grew the fastest in the entire life sciences landscape during the period 2009 – 2011. CALP was sold in late 2011 for $650M cash. Prior to the acquisition, he served as President and CEO of Zymark. Under Kevin’s leadership, Zymark was transformed from a custom robotics job shop into a leading life sciences tools and informatics company. Prior to this, Kevin was Director of International Business, Agricultural Chemical Division, and President of the Pharmaceutical Division, for FMC Corporation. From 1983 to 1992, he held several management positions at E.I. DuPont de Nemours, including North American Sales and Marketing Head, Teflon.
Hrusovsky currently sits on the Board of 908 Devices, the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. He formerly served on the boards of SeraCare, Caliper Life Sciences, Xenogen Corporation and Alliant Medical Technology. Hrusovsky received an Honorary Doctorate degree from Framingham State University for contributions in life sciences. He received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University.
In-Q-Tel is the not-for-profit, strategic investment firm that works to identify, adapt, and deliver innovative technology solutions to support the missions of the U.S. Intelligence Community. Launched in 1999 as a private, independent organization, IQT’s mission is to identify and partner with companies developing cutting-edge technologies that serve the national security interests of the United States. Working from an evolving strategic blueprint defining the Intelligence Community’s critical technology needs, IQT engages with entrepreneurs, startups, researchers, and investors to deliver technologies that provide superior capabilities for the CIA and broader Intelligence Community. For more information, visit www.iqt.org.
Dr. James W. Jorgenson
Dr. James W. Jorgenson is the William Rand Kenan, Jr. Distinguished Professor of Chemistry at the University of North Carolina in Chapel Hill. He was Chair of the UNC Chemistry Department from 2000 to 2005. Professor Jorgenson is one of the inventors of capillary electrophoresis (CE), and the originator of ultra-high pressure liquid chromatography (UHPLC). His current research interests include ultra-high pressure liquid chromatography, multidimensional separations, microscale separations coupled to mass spectrometry, and the application of this technology to proteomics and metabolomics.
Douglas Kahn is Executive Chairman of Tetragentics, Inc., an innovative life science company that developed a new technology for drug discovery. Mr. Kahn was previously Chairman & CEO of Ahura Scientific, Inc., the world’s leader in the design and manufacture of advanced ultra-compact spectroscopic instruments for safety, security and pharmaceutical applications. Prior to joining Ahura Scientific, Mr. Kahn served as President and CEO of PanAmSat Corporation, an international provider of satellite communications services and operator of a global fleet of 21 geostationary satellites. He also served as Chairman and CEO of Easel Corporation, a venture capital financed software company which he led through ten years of growth and a successful IPO. Mr. Kahn holds a BS in Operations Research and Industrial Engineering from Cornell University and an MBA from Stanford University.
Dr. Kevin J. Knopp
Dr. Kevin Knopp is a co-founder & CEO of 908 Devices Inc. An experienced high-tech entrepreneur, Kevin co-founded Ahura Scientific in 2002, and was Senior Vice President overseeing Operations, R&D and Safety and Security Sales through Ahura’s acquisition by Thermo Fisher Scientific in 2010, where he continued as Vice-President and Site Leader of the Portable Optical Analysis division. Kevin served as an independent board member for Crystal IS until its acquisition by Asahi-Kasei. He earned B.S.E.E from Boston University, M.S.E.E, and Ph.D. degrees in Optics from the University of Colorado. Kevin is an inventor on more than 20 US patents, is an author on more than a dozen refereed publications, and his products have received R&D 100, Business Week IDEA, GSN, CPhI Gold, Cygnus, and Frost & Sullivan awards.
Martin D. Madaus, PhD
Dr. Martin D. Madaus, Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. (OCD), has more than 25 years of experience in the diagnostics and life science industries.
Prior to joining OCD, Dr. Madaus served as Executive Chairman of Quanterix Corporation, and as Senior Healthcare Advisor to the Carlyle Group.
He was Chairman, President and Chief Executive Officer of Millipore Corporation (NYSE: MIL) from January 2005 to July 2010. In addition, Dr. Madaus was President and Chief Executive Officer of Roche Diagnostics Corporation from 2000 to 2004, where he served as head of North American Operations. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics, and served as the President of Roche Diagnostics Canada.
Dr. Madaus started his career in the Diagnostics Industry in 1989 at Boehringer Mannheim, Germany and served in various product management, marketing and general management roles in Germany, the United States and Canada.
Dr. Madaus has extensive public and private company board experience and currently serves on the board of Mettler-Toledo International Inc (NYSE: MTD) and Quanterix Corporation (private). In addition, he served as a Director of Covidien PLC (NYSE: COV), Millipore (NYSE:MIL), PPD International (private) and Predictive Bioscience (private).
Dr. Madaus received a Doctor of Veterinary Medicine degree from the University of Munich in Germany and a PhD in Veterinary Medicine from the Veterinary School of Hanover in Germany.
Dr. Alan G. Marshall
Dr. Alan G. Marshall is the Robert O. Lawton Professor of Chemistry and Biochemistry and Director of the Ion Cyclotron Resonance (ICR) Program at Florida State University. He co-invented and leads the continuing development of Fourier transform ICR mass spectrometry. His current research spans FT-ICR instrumentation development, fossil fuels and environmental analysis, and mapping the primary and higher-order structures of biological macromolecules and their complexes. He is a former President of the American Society for Mass Spectrometry, and serves on several editorial boards. He has published 4 books, 7 patents, and 570 refereed journal articles. His papers have been cited more than 24,500 times.
Paul Meister is President of MacAndrews & Forbes Incorporated. He is also co-founder of Liberty Lane Partners, LLC, a private investment company with investments in healthcare, technology, and distribution-related industries and Perspecta Trust, a trust company that provides trust and investment services. Mr. Meister previously served as Chairman and CEO of inVentiv Health, a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries.
Prior to that, he served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. During his tenure as an executive officer of Fisher Scientific, from 1991 to 2006, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively as operations grew from two countries to 27 and sales expanded into 140 countries worldwide.
Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company.
Mr. Meister holds a Bachelor of Arts degree from the University of Michigan and an MBA from Northwestern University. He is a director of LKQ Corporation, Scientific Games Corporation, Quanterix Corporation; co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.
Manuel O. Méndez
Manuel O. Méndez is Executive Vice President and General Manager of Americas Commercial Operations at bioMérieux. Prior to joining bioMérieux in 2010, Mr. Méndez served in various domestic and international executive leadership roles at Abbott Laboratories, Thermo Fisher Scientific, and Orasure Technologies. From 2007 to 2009, he served as Director of Global Sales, Marketing and Business Development at Thermo Fisher Scientific. Prior to that, he spent over two years as General Manager BENELUX (Belgium, Netherlands, and Luxembourg) Diagnostics Division, a division of Abbott Laboratories, based in Belgium. From 2003 to 2005, he served as President & GM of Abbott Korea.
Mr. Méndez has served as a member of the Board of Directors at VillageCare, a community-based, not-for-profit organization in New York City that is dedicated to serving senior persons living with HIV/AIDS as well as individuals in need of continuing care and rehabilitation services.
He received a B.S. degree in Biomedical Engineering from Boston University and an MBA degree from Northwestern University Kellogg School of Management.
Dr. J. Michael Ramsey
Dr. J. Michael Ramsey is the Goldby Distinguished Professor of Chemistry at the University of North Carolina – Chapel Hill. Dr. Ramsey is also the director of the UNC Center for Biomedical Microtechnologies, a center focused on fostering collaborations between medical researchers or clinicians and developers of microtechnologies for enhancing access to biological information. His present research interests include highly miniaturized mass spectrometry, micro- and nanofluidics, and single molecule DNA sequencing, single cell assays and point-of-care clinical diagnostic devices. Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), later renamed Caliper Life Sciences and acquired by PerkinElmer in late 2011 for $650M. Caliper is the leading commercial supplier of microfluidic technologies; tools primarily used in the pharmaceutical and biotechnology industries. Dr. Ramsey is also the scientific founder of 908 Devices Inc. and serves as chair of the Scientific Advisory Board.
Razor’s Edge Ventures
Razor’s Edge is a venture capital fund founded by a group of distinguished entrepreneurs and executives from the national security industry. Razor’s Edge invests in, and partners with, private technology companies serving the national security market exclusively or in combination with other commercial markets.
Razor’s Edge has a unique understanding of the national security community’s strategic priorities and works tirelessly to identify and deliver disruptive technologies capable of advancing critical mission needs. We vet technology every day under challenging circumstances where the stakes are high and schedules are unforgiving. The goal of Razor’s Edge is easily summarized but demands a broad cross-section of skills to attain: We will help innovative companies rapidly deliver unique capabilities to the Government customers who need them. For more information visit www.razorsvc.com.
Stephen V. Reeves
Steve Reeves is a highly accomplished senior executive and an internationally recognized expert on Chemical and Biological Defense and Defense Acquisition. Experienced in leading and managing large, diverse, and global, multi-billion dollar organizations, Reeves established, and for seven years led the first Department of Defense Joint Program Executive Office. Working with the White House, other cabinet departments and the Congress, Reeves was instrumental in developing national policy guidance for delivering both defense systems and medical devices and pharmaceuticals to U.S. Forces, international and coalition partners, and for Homeland Security as well as broader policy guidance for national chemical and biological defense and medical systems.
Also an expert in Defense Acquisition, Reeves has lectured extensively on Defense Acquisition both internationally and domestically, including at the National Defense University, and the Defense Acquisition University including for three years as the capstone speaker for the Senior Executive Course. Reeves was selected as the Army’s Project Manager of the Year, is a two-time winner of the Department of Defense David Packard Award for Acquisition Excellence, and received the U.S. Vice President’s Hammer Award for Innovation in Defense Contracting.
Dr. Nicolas H. Roelofs
Dr. Nicolas H. Roelofs, Ph.D., has more than 19 years of experience in the Life Sciences and Diagnostics industry, most recently as Senior Vice President and President of the Life Sciences Group at Agilent Technologies Inc. Dr. Roelofs joined Agilent from Bio-Rad where he served as Group Operations Officer of the protein separations and analysis, genomics and food science business. Previously he served as SVP of marketing & Asian sales at Stratagene Corp. and went on to lead the company as Chief Operating Officer responsible for all commercial operations. He also served as a Business Unit Director at Applied Biosystems. Dr. Roelofs received his Ph.D. in Organic Chemistry from the University of Nevada, Reno and an M.S. in Organic Chemistry from the University of Iowa.
Saudi Aramco Energy Ventures
SAEV is the corporate venturing subsidiary of the Saudi Arabian Oil Company (Saudi Aramco), the world’s leading fully integrated energy and petrochemical enterprise. Headquartered in Dhahran with offices in North America and Europe, SAEV’s mission is to invest globally in start-ups and high growth companies with technologies of strategic importance to its parent, Saudi Aramco.
Schlumberger (NYSE:SLB) is the world’s leading supplier of technology, integrated project management and information solutions to customers working in the oil and gas industry worldwide. Employing approximately 120,000 people representing over 140 nationalities and working in more than 85 countries, Schlumberger provides the industry’s widest range of products and services from exploration through production. Schlumberger Limited has principal offices in Paris, Houston and The Hague, and reported revenues from continuing operations of $41.73 billion in 2012. For more information, visit www.slb.com
At Razor’s Edge, Mr. Spoto is responsible for the fund’s day-to-day business operations. His primary responsibilities include the identification and evaluation of investment opportunities, market and industry analyses, deal structuring, fundraising, and LP relations, as well as support of and advice to Razor’s Edge portfolio companies. Prior to joining Razor’s Edge, Mr. Spoto was a partner in the Reston, Virginia office of Cooley LLP, a national law firm. He worked with many emerging and high growth technology companies and investment funds, and his practice focused on mergers and acquisitions, venture capital, private equity and public securities offerings, and general corporate representation. His operating company clients were engaged in high-growth industry sectors including software, government contracts, aerospace/defense, telecommunications, and media. From 2008-2011, Chambers USA named Mr. Spoto to its list of America’s Leading Lawyers for Business, and in 2009, he was selected by The Legal 500 as a leading lawyer in the fields of venture capital and emerging companies. Prior to practicing law, Mr. Spoto was an aerospace engineer, working on the Air Force Titan IV rocket program for McDonnell Douglas Space Systems Company. He holds a B.S. in Aerospace Engineering from Boston University and a J.D. from Georgetown University Law Center.
Artur Stankiewicz is Schlumberger’s Reservoir Laboratories Manager and Fluids Domain Head, and Advisor Reservoir Fluids and Geochemistry. Since joining Schulmberger in 2010, Artur has held technical management positions and is presently managing 27 rock and fluids laboratories. His achievements span influencing reorganization and growth of the reservoir fluids business through effective global management, supporting R&D efforts, and establishing aqueous and petroleum geochemistry competence and services. Prior to this he worked 12 years for Shell in various research and management positions around the world, taking post in the USA, the Netherlands and UAE. He was Shell’s Expert in the area of Geochemistry, Fluid Properties and Flow Assurance. Artur holds an MSc and PhD in Geology/Organic Geochemistry and spent 2 years as a Post-Doctoral Assistant at Bristol University, UK. He has authored more than 70 articles and 80 conference abstracts, and been an invited lecturer, organizer and chair of numerous international meetings and symposia. He is currently the Chair of the European Association of Organic Geochemists (EAOG), was SPE Distinguished Lecturer 2011/12 and a member of SPE, AAPG.
Cory Steffek is the Managing Director of North American at Saudi Aramco Energy Ventures (SAEV), the corporate venturing subsidiary of Saudi Aramco. He is responsible for identifying technology investments of strategic importance in the areas of: upstream oil & gas; downstream oil & gas and value-added products; renewable energy; energy efficiency and water.
Before joining SAEV, Cory was in Corporate Development and Strategy at First Solar, where he was responsible for strategic investments and acquisitions with emphasis on new technologies and products. Prior to First Solar, Cory was at the Altira Group, an energy-focused venture capital firm, where he led investments in a broad range of energy technology companies. In addition, he has also held several management roles in product development and engineering at PPG Industries. He holds a PhD in materials chemistry from the University of Michigan and an MBA from The Kellogg School of Management at Northwestern University.
University of Tokyo Edge Ventures
UTEC is an early stage technology focused venture capital firm associated with The University of Tokyo. UTEC was founded in 2004, the year the Japanese National University Reform took place. UTEC currently manages its funds of $175 million in total, investing in seed/early stage start-ups. Having proprietary access to the University’s inventions, UTEC works closely with its researchers as scientific founders to co-found companies, which will contribute to society through business based upon innovations. UTEC has invested in 46 companies with 8 IPO and 7 M&A exits to date. For more information visit www.ut-ec.co.jp.
Dr. Daryoosh Vakhshoori
Daryoosh Vakhshoori is the founder and CEO of Pendar Medical, a company pioneering point-of-care medical devices based on optical technologies. Dr. Vakhshoori is an inventor and veteran of high-tech industry. Leveraging his background in opto-electronics he previously founded several successful companies with a focus on purpose-built-solutions and strong commitment to team-based leadership. His technology breakthroughs have transformed industries from telecommunications, safety and security, pharmaceutical manufacturing and medical device development. In 2002 Dr. Vakhshoori was a founder of Ahura Scientific, a developer of transformative handheld Raman and FTIR instruments used for chemical analysis in the field. Ahura Scientific was acquired by Thermo Fisher Scientific in 2010. Dr. Vakhshoori was also co-founder and vice president of CoreTek, which was acquired by Nortel Networks ($1.4B) in 2000. Dr. Vakhshoori earned his Ph.D. in Quantum Electronics from U.C. Berkeley.
Dr. David R. Walt
David R. Walt is Robinson Professor of Chemistry at Tufts University and is a Howard Hughes Medical Institute Professor. Dr. Walt is the Scientific Founder and a Director of both Illumina Inc. and Quanterix Corp. He has published over 300 scientific papers and holds over 60 patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical sensors and arrays. He is a member of the National Academy of Engineering, a fellow of the American Institute for Medical and Biological Engineering, and a fellow of the American Association for the Advancement of Science.